Smith & Nephew strategy under new CEO, shares trade stable in London
22.06.2026 - 15:57:55 | ad-hoc-news.de
By Stefan Krueger, Long-Term & Business Model desk. Reviewed prior to publication on 2026-06-22, 15:56.
Smith & Nephew (GB0009223206) continues its longer-term turnaround under CEO Deepak Nath, with the shares trading in London and as an ADR on the NYSE. Analysts still highlight the margin gap to US peers such as Stryker and Zimmer Biomet as a core strategic challenge.
What recent coverage highlights
On the London Stock Exchange the Smith & Nephew shares most recently changed hands at around 1,119.5 pence, according to Irish broker Davy, implying a year-to-date performance that trails many US medtech names. The Davy data show an intraday range between 1,119.5 and 1,130 pence with a modest decline of 0.49 percent on the day.
Consensus data compiled by MarketBeat point to an average target price near 1,125 pence and a mixed analyst stance between Hold and Buy on the stock. That same overview shows a blend of international coverage, including houses in London and New York that compare Smith & Nephew’s profitability with S&P 500 healthcare constituents.
Strategy and margin ambitions
Since his appointment in 2022, CEO Deepak Nath has emphasized restoring margin quality across orthopedics, sports medicine and advanced wound management, supported by a company-wide program to improve efficiency and simplify the portfolio. Smith & Nephew’s US-listed ADR last traded around 30.07 dollars, underlining the group’s dual-venue visibility for international investors.
The strategy has focused on improving execution in reconstruction implants and trauma products while investing in faster-growing sports medicine and wound care segments, areas where peers like Stryker and Johnson & Johnson also report robust demand. Management has consistently framed mid-teens trading profit margins as an ambition, which remains below the high-teens to low-20s levels seen at the strongest US medtech names.
Background and price data on Smith & Nephew
Further figures, news flow and historical price data on the Smith & Nephew shares can be found in the dedicated topic overview on ad-hoc-news.de and in the group’s investor relations material.
The product behind the stock
Smith & Nephew generates a substantial share of its revenue from orthopedic reconstruction systems such as its Journey II knee implant family, alongside hip implants, trauma fixation products and sports medicine devices. Advanced wound dressings and negative-pressure therapy systems complement these surgical product lines in hospitals and outpatient settings.
Where the stock trades today
The Smith & Nephew shares (GB0009223206) trade on the London Stock Exchange at 1,119.5 pence as of 2026-06-22, 09:32, based on the latest available quote. The US ADR with ticker SNN last changed hands near 30.07 dollars on the NYSE on the same reporting date.
Smith & Nephew at a glance
- Company: Smith & Nephew plc
- ISIN: GB0009223206
- WKN: 922320
- Ticker: SN (London), SNN (NYSE)
- Trading venue: London Stock Exchange / NYSE (ADR)
- Price (as of 2026-06-22, 09:32): 1,119.5 pence (London)
- Market cap: around 9 billion pounds sterling (as of 2026-06-22)
- Sector / industry: Healthcare - Medical Devices
- Index membership: FTSE 100
- Next earnings date: not officially scheduled
This article is for information purposes only and does not constitute investment advice, an offer or a solicitation to buy or sell any financial instrument. Figures and dates are based on sources cited and may change without notice.
